Application seeking use of nivolumab and ipilimumab in the first-line treatment of metastatic non-small cell lung cancer withdrawn

The withdrawal of the application by Bristol-Myers Squibb Pharma EEIG was based on the CHMP’s consideration that data from the supporting study (CA209227 Part 1) do not allow the Committee to conclude on a positive benefit-risk balance.


European Medicines Agency